• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Diamyd Medical AB - Product Pipeline Review - Q4 2010 - Product Image

Diamyd Medical AB - Product Pipeline Review - Q4 2010

  • ID: 1446814
  • November 2010
  • 55 pages
  • Global Markets Direct

Diamyd Medical AB – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Diamyd Medical AB - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Diamyd Medical AB - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Diamyd Medical AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, READ MORE >



List of Tables
List of Figures
Diamyd Medical AB Snapshot
Diamyd Medical AB Overview
Key Information
Key Facts
Diamyd Medical AB – Research and Development Overview
Key Therapeutic Areas
Diamyd Medical AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Diamyd Medical AB – Pipeline Products Glance
Diamyd Medical AB – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Diamyd Medical AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Diamyd Medical AB–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Diamyd Medical AB – Drug Profiles
Diabecell
Product Description
Mechanism of Action
R&D Progress
Diamyd
Product Description
Mechanism of Action
R&D Progress
Diabecell
Product Description
Mechanism of Action
R&D Progress
Diamyd
Product Description
Mechanism of Action
R&D Progress
NP2
Product Description
Mechanism of Action
R&D Progress
NP2
Product Description
Mechanism of Action
R&D Progress
NTDDS NC3
Product Description
Mechanism of Action
R&D Progress
NTDDS NG2
Product Description
Mechanism of Action
R&D Progress
Diamyd Medical AB – Pipeline Analysis
Diamyd Medical AB – Pipeline Products by Therapeutic Class
Diamyd Medical AB Pipeline Products By Target
Diamyd Medical AB – Pipeline Products by Route of Administration
Diamyd Medical AB – Pipeline Products by Molecule Type
Diamyd Medical AB – Recent Pipeline Updates
Diamyd Medical AB – Company Statement
Diamyd Medical AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Nov 10, 2010: Diamyd Completes Screening For US Phase III study
Oct 19, 2010: Diamyd Reports Data From Chronic Pain Trial With NP2 Enkephalin
Sep 13, 2010: Diamyd Reports Promising Safety Findings From Phase I Study In Chronic Pain
Mar 24, 2010: Diamyd Medical Receives Orphan Drug Designation For Diamyd In US
Mar 24, 2010: Diamyd Medical Receives Orphan Drug Designation For Diamyd In US
Mar 10, 2010: Diamyd Medical Enrolls 100 Patients In Ongoing US Phase III Study Of Diabetes Drug
Jan 29, 2010: Diamyd To File Market Approval For The Diamyd Diabetes Vaccine In 2011
Dec 14, 2009: Diamyd Medical reports Approval For Studies Of Diamyd In Children Down To 3 Years Of Age
Nov 12, 2009: Diamyd Medical Announces Fully Recruitment Of Phase III Study Of Diamyd
Jun 08, 2009: Diamyd Medical Reports Phase III Approval Of Diamyd For Younger Patients In The US
Financial Deals Landscape
Diamyd Medical AB, Deals Volume Summary, 2004 to YTD 2010
Diamyd Medical AB, Deals Summary By Region, 2004 to YTD 2010
Diamyd Medical AB, Deals Summary, 2004 to YTD 2010
Diamyd Medical AB Detailed Deal Summary
Acquisition
Diamyd Medical Acquires Nurel Therapeutics
Equity Offering
Diamyd Medical Completes Rights Issue Of $31 Million
Diamyd Medical Raises $3 Million From Excise Of Warrants
Diamyd Medical Completes Private Placement Of $12 Million
Diamyd Medical Completes Private Placement Of $1.5 Million
Diamyd Medical Raises $7 Million On Exercise Of Warrants
Debt Offering
Protein Sciences Completes Private Placement Of Convertible Notes For $1 Million
Diamyd Medical Enters Into Agreement With NIDDK
Licensing Agreements
Diamyd Medical Enters Into Licensing Agreement For Endomorphin Technology
Diamyd Medical Enters Into Licensing Agreement With National Center for Scientific Research
Diamyd Therapeutics Enters Into Licensing Agreement With Neurologix
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS